Stryker's shares dropped 10% following a guidance cut that impacted sales more than earnings, with adjusted EPS slightly below expectations and revenue missing estimates. Challenges include slow growth in hips and knees markets, supply disruptions, and slower adoption of key products. Despite a strong MedSurg segment and margin improvements, the company lowered its 2026 sales growth forecast and expects a tougher 2027 starting point. New CEO Spencer Stiles faces the task of rebuilding and providing clearer guidance early next year.
Stryker Corporation's shares plunged 10.33% to USD 279.21 as of Oct 30, 2026 17:11 WIB on Pluang, reflecting significant investor reaction to the guidance cut. The stock trades near its 52-week low of USD 269.75, with a market cap of $119.58 billion and a dividend yield of 1.13%. Despite the sharp drop, all Pluang order activity remains on the buy side, showing continued investor interest amid the uncertainty faced by new CEO Spencer Stiles.
Stryker reported a 7.7% increase in net sales to $6.5 billion for Q3 2026, driven by organic growth in MedSurg, Neurotechnology, and Orthopaedics. Adjusted earnings per share rose 10.3% to $3.52, reflecting strong operational performance, while repor...
Stryker Corporation, a global leader in medical technologies, reported a 6.1% increase in revenue and EBITDA of $3.45 billion for the first half of 2026. Management forecasts organic revenue growth between 8.3% and 9.3% for the full year, with adjust...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
